Troy Wuertz
@Ikarian Capital, Llc
Latest period2024 - Q3ReportedManaged Assets$717.154MTotal holdings121
Assets growth rate24.93%Assets growth rate (2-Q avg)-6.06%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Ikarian Capital, Llc's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 121 positions.
Assets under management
The assets under management (AUM) of Ikarian Capital, Llc over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 717.154M in assets, with a quarterly growth rate of 24.93% and a 2-quarter average growth rate of -6.06%. The portfolio is managed by Troy Wuertz, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
RZLTRezolute Inc
| 0.61% | $4.303M 887,230 shares@ $4.86 avg price | Decreased -1.82% |
ABEOAbeona Therapeutics Inc
| 0.52% | $3.688M 583,593 shares@ $6.33 avg price | Decreased -24.08% |
SLRNAcelyrin Inc
| 0.47% | $3.338M 677,074 shares@ $4.94 avg price | Decreased -54.09% |
CRVOCervomed Inc
| 0.42% | $2.954M 202,345 shares@ $14.6 avg price | Decreased -14.74% |
TERNTerns Pharmaceuticals Inc
| 0.36% | $2.573M 308,497 shares@ $8.35 avg price | Decreased -32.71% |
CMPSCompass Pathways Plc
| 0.18% | $1.278M 202,908 shares@ $6.3 avg price | Decreased -33.01% |
SGMTSagimet Biosciences Inc
| 0.15% | $1.074M 387,565 shares@ $2.77 avg price | Decreased -6.05% |
JSPRJasper Therapeutics Inc
| 0.15% | $1.038M 55,175 shares@ $18.82 avg price | Decreased -47.53% |
RNACCartesian Therapeutics Inc
| 0.12% | $841,352 52,193 shares@ $16.13 avg price | Decreased -78.46% |
AVTEAerovate Therapeutics Inc
| 0.11% | $769,046 367,965 shares@ $2.09 avg price | Decreased -0.27% |